Please use this identifier to cite or link to this item:
http://hdl.handle.net/11607/3660| Title: | Endometrial kanserlerde PTEN ekspresyonunun prognostik faktörlerle karşılaştırılması |
| Authors: | Kurtulmuş, Yusuf Can, Mesut Aydın Adnan Menderes Üniversitesi, Sağlık Bilimleri Enstitüsü, Tıbbı Biyokimya Bölümü |
| Keywords: | Endometrium Kanser, PTEN, Real Time PCR, |
| Issue Date: | 2019 |
| Publisher: | Aydın Adnan Menderes Üniversitesi, Sağlık Bilimleri Enstitüsü, Tıbbı Biyokimya Bölümü |
| Citation: | Ali IU, Schriml LM, Dean M. Mutational Spectra of PTEN/MMAC1 Gene: a Tumor Suppressor With Lipid Phosphatase Activity. Journal of the National Cancer Institute 1999, 91 (22), 1922-1932. An HJ, Lee YH, Cho NH, Shim JY, Kim JY, Lee C, Kim SJ. Alteration of PTEN expression in endometrial carcinoma is associated with down‐regulation of cyclin dependent kinase inhibitör. Histopathology 2002, 41, 27. Ascher SM. Reinhold C. Imaging of cancer of the endometrium. Radiologic Clinics of North America 2002, 40(3), 563-76. Bansal N, Yendluri V, Wenham RM. The Molecular Biology of endometrial Cancer and the implications for pathogenesis, classification and targeted therapies. Cancer Control January 2009, 16(1), 8-13. Barrena Medel NI, Herzog TJ, Deutsch I, Burke WM, Sun X, Lewin SN, et al. Comparison of the prognostic significance of uterine factors and nodal status for endometrial cancer. American Journal of Obstetrics & Gynecology 2011, 204(3), 248. Bian X, Gao J, Luo F, Rui C, Zheng T, et al. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy. The Journal of Oncogene 2018, 37, 341–351. Bonneau D, Longy M. Mutations of the human PTEN gene. The Journal of Human mutation 2000, 16, 109. Buckley H, Fox H. Biopsy Pathology of the Endometrium, 2Ed: Taylor & Francis, 2002. Cornelison TL. Trimble EL, Kosary CL. SEER data, corpus uteri cancer: treatment trends versus survival for FIGO stage II, 1988-1994. The Journal of Gynecol Oncology 1999; 74(3), 350-355. Darvishian F, Hummer A, Thaler H, Bhargava R, Linkov I, Asher M, et al. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic an immunohistochemical study of a group of problematic cases. The American Journal of Surgical Pathology 2004, 28, 1568–1578. Detre S, Saclani Jotti G, Dowsett M. A “quickscore” for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. Journal of clinical pathology 1995, 48(9), 876-878. Djordjevic B, Hennessy BT, Li J, Barkoh BA, Luthra R, Mills GB, Broaddus RR. Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing. Modern Pathology 2012, 25, 699 – 708. Erkanlı S, Kayaselcuk F, Kuscu E, Bagıs T, Bolat F, Haberal A. Expression of survivin, PTEN and p27 in normal, hyperplastic, and carcinomatous endometrium. International Journal of Gynecological Cancer 2006, 16, 3. Gougelet A, Bouclier C, Marsaud V, Maillard S, Mueller SO, Korach KS, Renoir JM. Estrogen receptor and subtype expression and transactivation capacity are differentially affected by receptor- HSP90- and immunophilin-ligands in human breast cancer cells. Journal of Steroid Biochemistry & Molecular Biology 2005, 94, 71–81. Guzeloglu-Kayisli O, Kayisli UA, Al-Rejjal R, Zheng W, Luleci G, Arici A, Regulation of PTEN (phosphatase and tensin homolog deleted on chromosome 10) expression by estradiol and progesterone in human endometrium. The Journal of Clinical Endocrinology & Metabolism 2003, 88, 5017-5026. Hecht J, Mutter G. Molecular and pathologic aspects of endometrial carcinogenesis. Journal of clinical Oncology 2006, 4783-4791. Kapucuoğlu N, Aktepe F, Kaya H, Bircan S, Karahan N, Çiriş M. Immunohistochemical expression of PTEN in normal, hyperplastic and malignant endometrium and its correlation with hormone receptors, bcl-2, bax, and apoptotic index. Pathology - Research and Practice 2007, 3, 153-162. Kim BW, Jeon YE, Cho H, Nam EJ, Kim SW, Kim S, et al. Pre-treatment diagnosis of endometrial cancer through a combination of CA125 and multiplication of neutrophil and monocyte. Journal of Obstetrics and Gynaecology 2012, 38 (1), 48-56. Kim JW, Kim SH, Kim YT, Kim DK. Clinicopathologic and biological parameters predicting the prognosis in endometrial cancer. Yonsei Medical Journal 2002, 43(6), 769-778. Kimura F, Watanabe J, Hata H, Fujisawa T, Kamata Y, Nishimura Y, Jobo T, Kuramoto H: PTEN immunohistochemical expression is suppressed in G1 endometrioid adenocarcinoma of the uterine corpus. Journal of cancer research and clinical oncology 2004, 130, 161-168. Kiyoshi I, Watanabe K, Nasim S, Sasano H, Sato S, Yajima A, et al. Prognostic Significance of p53 Overexpression in Endometrial Cancer. American Journal of Cancer Research 1994, 54:4667. Klinc P, Rath D. Reduction of oxidative stress in bovine spermatozoa during flow cytometric sorting. The Journal of Reproduction in Domestic Animals 2007, 42(3), 63–67. Konopka B, Janiec-Jankowska A, Czapczak D, Paszko Z, Bidziński M, Olszewski W, Goluda C: Molecular genetic defects in endometrial carcinomas: microsatellite instability, PTEN and beta-catenin (CTNNB1) genes mutations. Journal of cancer research and clinical oncology 2007, 133, 361-371. Konopka B, Paszko Z, Janiec-Jankowska A and Goluda M. Assessment of the quality and frequency of mutations occurrence in PTEN gene in endometrial carcinomas and hyperplasias. Journal of Cancer Letters 2002, 178: 43-51. Kurman RJ. International Agency for Research on C, World Health O: WHO classification of tumours of female reproductive organs. Lyon: International Agency for Research on Cancer, 2014. Kwon JS, Qiu F, Saskin R, Carey MS. Are uterine risk factors more important than nodal status in predicting survival in endometrial cancer? American Journal of Obstet Gynecology 2009; 114(4), 736-743. Laas E, Ballester M, Cortez A, Gonin J, Daraï E, Graesslin O. Supervisedclustering of immunohistochemical markers to distinguishatypical endometrial hyperplasia from grade 1 endometrial cancer. The Journal of Gynecologic Oncology 2014, 133, 205–210. Lacey JV, Mutter GL, Ronnett BM, Ioffe OB, Duggan MA, Rush BB, Glass AG, Richesson DA Chatterjee N, Langholz B. PTEN expression in endometrial biopsies as a marker of progression to endometrial carcinoma. American Journal of Cancer research 2008, 68, 6014-6020. Levine A, Momand J, Finlay C. The p53 tumour suppressor gene. Nature Research of the Journal 1991, 351, 453-456. Levine RL, Cargile CB, Blazes MS, van Rees B, Kurman RJ, Ellenson LH: PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma. American Journal of Cancer research 1998, 58, 3254-3258. Lewin SN, Herzog TJ, Barrena Medel NI, Deutsch I, Burke WM, Sun X, et al. Comparative performance of the 2009 international Federation of gynecology and obstetrics' staging system for uterine corpus cancer. The Journal of Obstetrics Gynecology, 2010, 116(5), 1141-1149. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Journal of Science 1997, 275, 1943–1947. Maehama T, Dixon JE. The tümör suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3.4.5-trisphosphate. Journal of Biological Chemistry 1998, 13, 375-378. Mariani A, Sebo T, Katzmann J, Keeney G, Roche P, Lesnick T, et al. Pretreatment assessment of prognostic indicators in endometrial cancer. American Journal of Obstetrics and Gynecology 2000, 182, 1535-1544. Maxwell GL, Risinger JI, Gumbs C, Shaw H, Bentley RC, Barrett JC, Berchuck A, Futreal PA. Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias. The Journal of Cancer research 1998, 58, 2500-2503. Mazières J, Brugger W, Cappuzzo F, Middel P, Frosch A, Bara I, Klingelschmitt G, Klughammer BA. Evaluation of the EGFR protein expression by immunhistochemistry using H-score and the magnification rule: re-analysis of the SATURN study. American Journal of Lung Cancer 2013, 82(2), 231-237. Moore KL, Dalley AF. Clinically oriented anatomy. Philadelphia: Lippincott Williams & Wilkins 1999. Moore KM, Persaud TVN. Klinik Yönleri İle İnsan Embriyolojisi. (Eds, Yıldırım M.) İkinci baskı, Nobel Tıp Kitabevi 2002, s:323- 325. Morrow CP, Bundy BN, Kurman RJ, Creasman WT, Heller P, Homesley HD, Graham JE. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: A Gynecologic Oncology Group study. American Journal of Gynecologic Oncology 1991, 40(1), 55-65. Morton DA, Peterson KD, Albertine KH, Morton DA. Gray's dissection guide for human anatomy. Philadelphia, PA: Churchill Livingstone Elsevier 2007. Mutter G, Lin M, Fitzgerald J, Kum J, Baak J, Lees A. Altered PTEN Expression as a Diagnostic Marker for the Earliest Endometrial Precancers. Journal of the National Cancer Institute 2000, 92, 924-930. Mutter GL, Ince TA, Baak JP, Kust GA, Zhou X-P, Eng C. Molecular identification of latent precancers in histologically normal endometrium. American Journal of Cancer research 2001, 61, 4311-4314. Mutter GL, Lin MC, Fitzgerald JT, Kum JB, Baak JP, Lees JA, Weng LP and Eng C. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl The National Cancer Institute 2000, 92, 924 – 930. Mutter GL, Lin M-C, Fitzgerald JT, Kum JB, Eng C. Changes in Endometrial PTEN Expression throughout the Human Menstrual Cycle 1. The Journal of Clinical Endocrinology & Metabolism 2000, 85, 2334-2338. Myers MP, Stolarov JP, Eng C, Li J, Wang SI, Wigler MH, Parsons R, Tonks NK. PTEN, the tumor suppressor from human chromosome 10q23, 73 is a dual-specificity phosphatase. The Proceedings of the National Academy of Sciences of the United States of America 1997, 94 (17), 9052-9057. Nehad MR, El-Maqsoud A, El-Gelany S. Differential expression patterns of PTEN in cyclic, hyperplastic and malignant endometrium: its relation with ER, PR and clinicopathological parameters. Journal of the Egyptian National Cancer Institute 2009, 21, 323-331. Ngai NC. Loss of LKB1 in High-Grade EndometrialCarcinoma: LKB1 is a Novel Transcriptional Target of p53. American Journal of Clinical Cancer 2014, 2. Nicholas Z, Hu N, Ying J, Soisson P, Dodson M, Gaffney DK. Impact of comorbid conditions on survival in endometrial cancer. American Journal of Clinical Oncology 2014, 37(2), 131-134. Peng WX, Kudo M, Fujii T, Teduka K, Naito Z. Alteredexpression of fibroblast growth factor receptor 2 isoform III c: relevance to endometrioid adenocarcinoma carcinogenesis and histological differentiation. International Journal of Clinical and Experimental Pathology, 2014, 7(3), 1069-1076. Potischman N, Hoover RN, Brinton LA, Siiteri P, Dorgan JF, Swanson CA, Berman ML, Mortel R, Twiggs LB, Barrett RJ, Wilbanks GD, Persky V and Lurain JR. Case-control study of endogenous steroid hormones and endometrial cancer. Journal of the National Cancer Institute 1996, 88, 1127-1135. Pugazhannthi S, Khandelwai RL. Insulin-like effects of vanadate on hepatic glycogen metabolism in nondiabetic and streptozotocin induced diabetic rats. The Journal of Diabetes 1990, 39, 821-827. Reddy P, Liu L, Adhikari D, Jagarlamudi K, Rajareddy S, et al. Oocyte specific deletion of Pten causes premature activation of the primordial follicle pool. American Journal of Science 2008, 319, 611–613. Risinger JI, Hayes AK, Berchuck A, Barrett JC. PTEN/MMAC1 mutations in endometrial cancers. American Journal of Cancer research 1997, 57, 4736-4738. Risinger JI, Hayes K, Maxwell GL, Carney ME, Dodge RK, Barrett JC, Berchuck A: PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clinical Cancer Research 1998, 4, 3005-3010. Romano C, Schepis C. PTEN gene: a model for genetic diseases in dermatology. The Scientific World Journal Volume 2012. Rosai J. Femalere productivesystem In: Ackerman’s surgical pathology. 9th. ed. St. Louis: Mosbyyearbook 2004, s 1569–1639. Rosai J. Rosai and Ackerman's Surgical Pathology: Elsevier Health Sciences, 2011. Ross HM, Pawlina W. Histoloji Konu Anlatımı ve Atlas İlişkili Hücre Biyolojisi ve Moleküler Biyoloji ile 2014, s784-809. Salvesen HB, Stefansson I, Kretzschmar EI, Gruber P, MacDonald ND, Ryan A, Jacobs IJ, Akslen LA, Das S. Significance of PTEN alterations in endometrial carcinoma: a population-based study of mutations, promoter methylation and PTEN protein expression. International journal of oncology 2004, 25, 1615-1623. Samarnthai N, Hall K, Yeh IT. Molecular Profiling of endometrial Malignancies. Obstetrics and Gynecology International 2010. Scully MM, Palacios-Helgeson LK, Wah LS and Jackson TA. Rapid estrogen signaling negatively regulates PTEN activity through phosphorylation in endometrial cancer cells. American Journal of Horm Cancer 2014, 5, 218 - 231. Setchell BP. The effects of heat on the testes of mammals. The journal of Animal Reproduction 2006, 3(2), 81-91. Sorosky JI. Endometrial cancer. American Journal of Obstetrics & Gynecology 2012, 120(2), 383-397. Stavropoulos A, Varras M, Vasılakakı T, Varra VK, Tsavarı A, Varra Fn, Nonnı A, Kavantzas N, Lazarıs A.C. Expression of p53 and PTEN in human primary endometrial carcinomas: Clinicopathological and immunohistochemical analysis and study of their concomitant expression. International Journal of Oncology and Letter 2019, 17(5), 4575–4589. Tang D, Chang L, Tavis W and Frierson H. Mutations of PTEN/MMAC1 in Primary Prostate Cancers from Chinese Patients. American Journal of Clinical Cancer Research 2001, 7, 304-308. Tashiro H, Blazes M, Wu R, Cho K, Bose S, Wang S, et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. American Journal of Cancer Research, 1997, 39, 35-40. Tashiro H, Isacson C, Levine R, Kurman R, Cho K and Lora Hedrick. p53 Gene Mutations Are Common in Uterine Serous Carcinoma and Occur Early in their Pathogenesis. The American Journal of Pathology 1997, 1, 68-70. Trovik J, Wik E, Stefansson I, Marcickiewicz J, Tingulstad J, Staff A, et al. Stathmin Overexpression Identifies High-Risk Patients and Lymph Node Metastasis in Endometrial Cancer. American Association for Cancer Research 2011, 17, 3368-3377. Turgut A, Özler A, Sak ME, Evsen ME, Soydinç HE, Başaranoğlu S. Retrospective Analysis of the patients with gynecological cancer: 11-Year Experience. Journal of Clınıcal and Experımental Investıgatıons 2012, 3, 209-213. |
| Abstract: | ENDOMETRİAL KANSERLERDE PTEN EKSPRESYONUNUN PROGNOSTİK FAKTÖRLERLE KARŞILAŞTIRILMASI CAN M. Aydın Adnan Menderes Üniversitesi Sağlık Bilimleri Enstitüsü Tıp Fakültesi Tıbbi Biyokimya (Tıp) Programı, Yüksek Lisans Tezi, Aydın, 2019. Endometrium kanseri günümüzde kadınlarda görülen kanserler içinde dördüncü sıradadır ve Amerika’da en sık görülen kadın kanseridir. Endometriyal karsinomlar kadın genital sisteminin en sık görülen malign tümörü olup, %80-85 olguda östrojen bağımlı iken, %10-15 olguda östrojen bağımlı değildir. Endometriyal karsinomlar tip I ve tip II olmak üzere iki gruba ayrılmaktadır. Tip I endometriyal karsinomlar anovulasyon ya da östrojen replasman tedavisi öyküsüne sahip 40-60 yaşları arasındaki genç hasta grubunda görülür. Genellikle iyi diferansiye, miyometriyum invazyonu olmayan ve endometriyal hiperplazi ile ilişkili olan karsinomlardır. Tip II endometriyal karsinomlar ise hiperplazi ve östrojen fazlası ile ilişkisi olmayan saldırgan tümörlerdir. Bunlar endometriyal atrofi zemininden gelişirler. Hastalar daha çok postmenapozal dönemde olup, tip I tümörlere göre daha ileri yaştadır. Tümör supresör gen PTEN (phosphatase ve tensin homolog), endometrial kanserlerde sıklıkla mutasyona uğrayan genlerdir. PTEN, tümör supresor gendir ve mutasyon oranı %30-50’dir. PTEN, 10.kromozomun uzun kolunda (q), 23.3 pozisyonunda lokalize olup, primer hedefi PIP3 adı verilen lipid molekülü olan, bir fosfataz kodlar. PIP3, hücre büyümesi ve apoptozu regüle eden sinyal iletim yolu üzerinde çalışır. PTEN ayrıca, iki hücre iskelet proteini ile büyük homoloji gösterir. Bu da hücre adezyon ve migrasyonunda da etkili olduğuna işaret eder. PTEN’ in, tümör büyümesinde supresor, gelişim ve metastazında ise inhibitör rol oynadığı gösterilmiştir. PTEN geninde homozigot ve heterozigot delesyon olan farelerle yapılan deneyde, PTEN tümör supresor genin gelişim sırasında oldukça önemli rolü olduğu izlenmiştir. PTEN inaktivasyonunun, histomorfolojik değişikliklerin yokluğunda bile görüldüğü tanımlanmıştır. Hiperplazilerde de yaklaşık %20 oranında görülür. Bu bulgular, PTEN inaktivasyonunun, endometrioid karsinom patogenezinin erken basamaklarında etkili olduğunu düşündürmektedir. Bu çalışmada amacımız, düşük yaş aralığındaki tip 2 endometrial kanserlerde erken basamaklarda geliştiği düşünülen PTEN proteinin ekspresyonundaki değişiklikleri Real time PCR, immunohistokimyasal yöntemler ile rutin prognostik parametrelerle karşılaştırılarak, değerlendirmektir. |
| URI: | http://hdl.handle.net/11607/3660 |
| Appears in Collections: | Yüksek Lisans |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| ENDOMETRİAL KANSERLERDE PTEN EKSPRESYONUNUN PROGNOSTİK FAKTÖRLERLE KARŞILAŞTIRILMASI%0D %0D %0D %0D MESUT CAN%0D YÜKSEK LİSANS TEZİ | 2.19 MB | Unknown | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.